Global HIV Breakthrough: HIV Shield For $40

Vial of clear liquid with syringe on a white surface — Photo: Todorean-Gabriel / Shutterstock

The Food and Drug Administration (FDA) gave tentative approval to the first generic version of a twice-yearly HIV prevention shot, opening the door to a $40-a-year option for people in 120 lower-income countries.

Quick Take

Dr. Reddy’s Laboratories announced the FDA tentatively approved its generic injectable lenacapavir for HIV prevention.
The branded version of the drug can cost more than $28,000 a year in the United States.
The generic is tied to a planned price near $40 per person per year under global access deals.
Tentative approval does not allow U.S. commercial sale while the original drug’s patents remain active.

What The FDA Actually Approved

Dr. Reddy’s told Reuters on November 2 that the FDA tentatively approved its generic injectable lenacapavir, a shot given twice a year to prevent HIV infection. Clinton Health Access Initiative and other health outlets called it the first generic injectable lenacapavir to reach this milestone, a notable step for a drug that has drawn global attention since its original approval. The product targets the same prevention use as the brand-name version, delivered through an injection rather than a daily pill.

Tentative approval is a specific FDA tool, not full market clearance. The agency uses it when a generic drug meets all safety and quality standards but cannot be sold in the United States yet because the original drug still holds patent or exclusivity protection. The FDA has used this process since 1984 for generic drugs tied to its PEPFAR program, which supports HIV treatment and prevention in lower-income nations.

Why The Price Tag Matters So Much

The gap between the brand-name shot and this generic version is enormous. One published review notes the original lenacapavir carries a U.S. price above $28,000 per year, while production cost estimates run closer to $25 per person annually. Dr. Reddy’s generic is expected to sell for about $40 per person per year, a price built around deals meant to reach people who could never afford the branded product.

That price depends on more than FDA action alone. Gilead, the company that developed lenacapavir, created a voluntary licensing arrangement allowing several generic manufacturers to produce and sell the drug in 120 mostly low- and middle-income countries. The FDA’s tentative approval makes Dr. Reddy’s version eligible for purchase through U.S. government programs like PEPFAR, which funds HIV prevention and treatment abroad, even though the drug still cannot be sold on U.S. pharmacy shelves.

Supplies Are Expected Before Year’s End

Reports tied to the announcement say supplies could begin reaching some of the 120 covered countries by the end of 2026. That timeline relies on a chain of steps beyond the FDA, including country-level drug registration, procurement contracts through groups like Unitaid and the Global Fund, and actual shipment of doses to clinics on the ground. The FDA’s green light clears one major hurdle, but it is not the final one.

Health researchers have also flagged that lenacapavir’s benefits depend on correct use. One academic review described the drug’s rollout as a breakthrough still facing real-world obstacles tied to pricing and licensing terms across different countries. Patients must test negative for HIV before starting the shot and before each follow-up injection, since using it without that testing has been linked to drug resistance in people who already carry undiagnosed infection.

A Long-Running Pattern In Global Health Policy

This is not the first time a tentative approval has served as a bridge between American drug regulation and global health funding. The FDA’s own materials describe the practice as common in its generic drug office for decades, built specifically to help PEPFAR-funded programs get affordable medicines moving while patent disputes play out domestically. Voluntary licensing deals, like the one covering lenacapavir, have followed a similar playbook for other HIV drugs in the past.

For American taxpayers and policymakers, the arrangement reflects a long-standing bargain. The United States helps fund and regulate medicines that never touch the domestic commercial market, aiming instead to slow a global epidemic at a fraction of the branded price. Whether the $40 price and 2026 supply target hold up will depend on licensing follow-through, country registrations, and funding commitments still working their way through the system.

The tentative approval marks a clear regulatory milestone, even as the harder work of delivery, pricing follow-through, and country-by-country rollout continues separately from the FDA’s decision.